Overview
Replimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year
Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025
Outlook
Replimune expects FDA decision on RP1 BLA by April 2026
Company plans to fund operations into late 2026
Result Drivers
R&D EXPENSES - Increase in R&D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3
FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progress
CLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancers
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$83.10 mln | ||
Q2 Basic EPS | -$0.90 | ||
Q2 Cash & Investments | $323.60 mln | ||
Q2 Operating Expenses | $84.29 mln | ||
Q2 Operating Income | -$84.29 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Replimune Group Inc is $12.50, about 31.4% above its November 5 closing price of $8.58
Press Release: ID:nGNX8P8Bvy
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)